Conferences / Events


  • No events scheduled. Please check back soon!


Brain Tumor News!


Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!

Displaying Stories 1 to 20 of 6,420
Next 20


09/20/18 Experimental drug 'nothing short of miraculous' for father of 4 with super-rare brain tumor        

 This is the drug that we recently gave a million dollar grant to help support and speed up it's development!  The mutation (H3K27 M)
 is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients.  This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation.  If you do, contact us and we can help you find a trial. (It is so common in DIPG that  no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)




09/17/18 Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.        

 I love this type of research.  Invadopoia are small projections from the edges of tumnor cells that help allow them to move.  Without the ability to move, the tumor is much less dangerous and more sensitive to normal treatments. This is a highly underappreciated target and they found 2 existing drugs which may target this.  Of course, it is just theory now and needs to be tested but it is a promising approach!




09/14/18 Brain Tumor Webinar Series: Gamma Knife Radiosurgery Sunday, 9/16/18        

 Dr Schulder will be speaking about the new version of the Gamma Knife, but will also answer questions on any brain tumor related topic!




09/14/18 Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition.        

 I am a big fan of Optune. It is the most effective approved treatment for gbms,  but it is not good enough by itself. We need to find ways to make it work better.  There are about 16 clinical trials going on now that involve Optune and ways to make it work better.   Any of these trials are worthwhile to try.  Experiments like this are needed to identify candidates for the trials. 




09/13/18 Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson        

 This is a new STAT3 inhibitor. STAT3 has been known as a good target for brain tumors but until now we did not have a good drug to target it. This was just the first in human doses of the drug so it is way too early to tell if it will work, but it may become an important tool in the ultimate cocktail.




09/13/18 Researchers make breakthrough in understanding aggressive brain cancer        

 Researchers at Duke identified why brain tumor patients have such low t cell counts - as low as that of AIDs patients.  Now we just need to figure out how to use this information!




09/10/18 Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas        

 This project will speed up the development of a drug (Onc-201) that has shown promise in early trials for DIPG as well as high grade gliomas that have a specific mutation called H3 K27m. If you have DIPG or a high grade glioma with that mutation, give us a call.

 This is a one million dollar grant, to be paid in 4 equal payments over the next 3 years. We gave the first $250,000 payment today!  I am going to need help raising the rest of the money!  This is one of the most important projects that we have ever worked on and we need to raise the money for the next payment in a few months.  Contact us for details.

 




09/10/18 NCI and Musella Foundation Award Grants for ONC201 Trials in Adult and Pediatric Brain Tumors        

 I would like to emphasis that this is a collaboration between the Musella Foundation, the Cure Starts Now Foundation, and the Michael Mosier Defeat DIPG Foundation! we couldn't have done this without them. 

 




09/10/18 Intra-tumoral treatment with oxygen-ozone in glioblastoma: A systematic literature search and results of a case series        

 Interesting results, but in a small number of patients.




09/06/18 Optune Open House: St. Louis, MO        

 These are nice meetings for anyone who has a brain tumor or cares for someone with a brain tumor




09/06/18 KKCO - Daybreak Anchor Sarah Schwabe's Connection To Glioblastoma        

 A video segment about glioblastoma




09/04/18 Dellann Elliott Mydland, President of the EndBrainCancer Initiative, to Serve on Two National Clinical Trial Committees for NRG Oncology, an NCI-Funded Research Group        

Congratulations to my good friend Dellann!  She is the perfect person for that job which hopefully will result in better, more "patient friendly" clinical trials!




09/04/18 Musella Foundation Copay Assistance Program is now open!        

 We have not received any new funding but a few grants expired and we recycle the funds, so we have enough money to only make a few grants.




09/01/18 This brain cancer drug stock has been on a tear        

 I usually do not report on financial stuff, but this is good news for the brain tumor community.  It shows that a brain tumor treatment can be a financial success and this will encourage other companies to enter this space!




08/29/18 Optune open house Seattle, WA        

 These are always very interesting and worth going for anyone dealing with a brain tumor.




08/27/18 Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib impairing VEGF-related signaling.        

 Interesting study - but it is only in the test tube. We follow Aspirin in the virtual trial but nobody has recorded it - I know many people must be taking it long term for heart protection - they just aren't recording it. If you are in the virtual trial and take long term Aspirin , please go back and post an update so we can see if it helps!




08/24/18 New glioblastoma clinical trial: mTOR inhibitor ABI-009        

 This is a new trial for newly diagnosed GBM or recurrent high grade glioma in adults (age 18+).






08/23/18 Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.        

 This drug has a strange past - it did very good in early trials for breast cancer but failied in the large phase 3 trial.  It seems to have lottle toxcicity and the early brain tumor trial showed good results so it is worth a try again






Displaying Stories 1 to 20 of 6420
Next 20